NM_000329.3(RPE65):c.124C>T is a missense variant that replaces leucine with phenylalanine at position 42. This variant is present in gnomAD v.4.1.0 at a Grpmax allele frequency of 0.00003588, with 7 alleles / 91068 total alleles in the South Asian population, which is lower than the ClinGen LCA/eoRD VCEP PM2_Supporting threshold of <0.0002 (PM2_Supporting). This variant has been reported in at least 2 probands with early-onset severe retinal dystrophy who were compound heterozygous with either the NM_000329.3(RPE65):c.130C>T (p.Arg44Ter) variant (PMID: 30996589) or the NM_000329.3(RPE65):c.495+1dup variant (VCEP member-provided data) suspected in trans, both of which were previously classified pathogenic by the ClinGen LCA/eoRD VCEP (1 total point, PM3). At least one proband harboring this variant exhibits a phenotype including diagnosis of Leber congenital amaurosis (0.5 pts) with onset in the first few months of life (1 pt), genotyping by targeted exome sequencing focused on 194 IRD genes without identifying an alternative basis for disease (2 points), poor vision limited to hand movement (1 pt), nystagmus (1 pt), maculopathy (0.5 pts), peripheral hyperpigmentation, and retinal vascular attenuation (0.5 pts), which together are specific for RPE65-related recessive retinopathy (total 6.5 points, PMID: 30996589, PP4). The computational predictor REVEL gives a score of 0.879, which is above the ClinGen LCA/eoRD VCEP threshold of ≥0.773 and predicts a damaging effect on RPE65 function (PP3_Moderate). The splicing impact predictor SpliceAI gives a score of 0.01 for acceptor gain, which is below the ClinGen LCA/eoRD VCEP recommended threshold of ≥0.2 and does not strongly predict an impact on splicing. A molecular dynamics and simulation-based model of the variant predicts that the variant would destabilize the structure of RPE65 (PMID: 32072079). However, this is not currently an approved form of functional evidence, so the PS3_Supporting code is not met. In summary, this variant meets the criteria to be classified as Likely Pathogenic for RPE65-related recessive retinopathy based on the ACMG/AMP criteria applied, as specified by the ClinGen LCA/eoRD VCEP: PM2_supporting, PM3, PP3_Moderate, and PP4. (VCEP specifications version 1.0.0; date of approval 09/21/2023).